Video-Delivered Emotion-Focused Mindfulness Therapy for late-life anxiety: Study Protocol for a Feasibility Randomized Controlled Trial During COVID-19

Stacey Elinor Hatch (18seh@queensu.ca)  
Queen’s University  https://orcid.org/0000-0001-8866-1708

Dorothy Kessler  
Queens University

Marcia Finlayson  
Queens University

Soham Rej  
McGill University

Study Protocol

Keywords: late life anxiety, mindfulness, meditation

DOI: https://doi.org/10.21203/rs.3.rs-179088/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: The worldwide prevalence of anxiety in older adults is estimated at between 6% and 10%. In Canada, adults 65 and older experience anxiety at a rate of 6.4%, affecting more than 300,000 people. Anxiety in older adults has been linked to difficulties retaining new information and engaging in instrumental daily activities of living. Due to COVID-19 restrictions, novel methods of delivering therapy programs remotely are needed, however data is limited. There is some evidence that older adults prefer non-pharmacological approaches for anxiety that can be delivered in the community. Emotion-Focused Mindfulness Therapy (EFMT) is a mindfulness-based intervention that emphasizes meditation and observing thoughts and emotions as they arise. This emphasis has been demonstrated to reduce symptoms of anxiety in general populations. This study aims to evaluate the feasibility of EFMT with older adults.

Methods: This pilot feasibility randomized controlled trial will use a wait list control trial design. Due to COVID-19 restrictions, we will use telehealth delivery via Zoom rather than in-person delivery. The first 48 people to meet the eligibility criteria will be randomly allocated to either receive EFMT immediately, or in approximately eight weeks time from enrollment (1:1 allocation ratio). Data will be collected at baseline, eight weeks following baseline, and sixteen weeks following baseline. The primary outcomes will determine the feasibility of the intervention based on recruitment, enrolment, retention and adherence to all components of the intervention. The secondary outcome will be changes to anxiety over time.

Discussion: The results of this trial will determine the feasibility and potential effectiveness of video-delivered EFMT for late-life anxiety compared to no treatment. If the results are promising, a larger randomized controlled trial may be conducted.

Trial registration: ClinicalTrials.gov: NCT04415528. Registered on June 4, 2020

Protocol version: Protocol version 2, January 2, 2021

Introduction

Background and rationale

The worldwide prevalence of anxiety in older adults is estimated at between 6% and 10% (1, 2). However, actual numbers may be higher because anxiety frequently goes undiagnosed in adults 65 and older, although symptoms such as insomnia, irritability and agitation are reported to primary care providers (3). This high prevalence of anxiety is of concern because anxiety is linked to decline in memory and is a leading cause of disability in older adults (4–7). In a study of 79 older adults, those with anxiety showed a greater decline in memory over a four year period (5). The worldwide prevalence of cognitive impairments has been estimated at between 10% and 20% in people over 65 (8–13). MCI can be understandably troubling for those living with the condition because MCI may be a prodromal symptom of dementia, with up to 15% of people progressing to dementia (14).

Anxiety in older adults has also been linked to negative effects on quality of life, problems managing stress, difficulty retaining new information, and sleep disturbances (15–17). Older adults who self-report anxiety, depression or both also experience a decline in functional activities, difficulties with the instrumental activities of daily living, increased mortality due to illness, suicidal ideation particularly among men, and increased use of health care services (3, 18). Present treatments for anxiety in adults 55 and older have met with limited success. While pharmacotherapy is frequently used to manage symptoms of anxiety in older adults, this approach has been related to negative side effects such as cardiovascular issues and falls (3, 19–22). Older adults favour non-pharmacotherapy approaches, such as psychotherapy, but do not always have access to public mental health care, or can afford private mental health care (3, 23). Given the increased rates of anxiety due to COVID-19, there is an identified urgent need for evidence based alternatives to pharmacotherapy for the treatment of anxiety that are feasible, potentially scalable, and can be delivered at the primary care and community levels (23, 24).

Mindfulness-based interventions (MBIs) in the treatment of anxiety, depression or anxiety comorbid with depression are an emerging area of research interest (25–29). MBIs offer a guided non-judgemental approach to attending to one's lived experiences through techniques such as meditation and psychoeducation (30–32). Other techniques include cultivating a focus on the present moment with self-compassion (30–32). Emotion Focused Mindfulness Therapy (EFMT) is a MBI that emphasizes meditation, and observing thoughts and emotions as they arise (28). EFMT has been demonstrated to reduce symptoms of anxiety in general populations (33, 34). EFMT’s focus on meditation and the felt sense of emotions, rather than learning new material, makes it a promising intervention for reducing symptoms of anxiety for older adults who often report normal aging problems such as general forgetfulness and difficulty with word recall (8). EFMT has not yet been tested in older adults. Currently, no studies to date have examined the feasibility of EFMT for community dwelling adults with anxiety. It is hypothesized that EFMT will be feasible for community dwelling older adults who experience anxiety.
Participants, interventions, and outcomes

This study aims to evaluate the feasibility of EFMT for community dwelling adults 55 and older with symptoms of anxiety. The secondary outcomes will be measurements of changes to anxiety, sleep and subjective memory functioning over time.

Objectives

Primary objectives:

1. Determine if participants can be recruited, enrolled, and retained.
2. Determine if participants can adhere to all components of the intervention.

Secondary objectives:

1. Determine the extent to which participants who receive the intervention have decreased levels of anxiety compared to those who do not receive the intervention.
2. Determine the extent to which participants have improved sleep quality compared to those who do not receive the intervention.
3. Determine the extent to which participants who receive the intervention have improved subjective memory functioning compared to those who do not receive the intervention.

Design and setting

The study is a feasibility randomized controlled trial (RCT) using a wait list control trial design. Due to COVID-19 restrictions, this study has been adapted from in person delivery to telehealth delivery via Zoom. The first 48 people to meet the eligibility criteria will be randomly allocated to receive EFMT immediately, or in eight weeks from time of baseline assessment (1:1 allocation ratio). Data will be collected by a blinded-to-group research assistant (RA) at baseline (T1), eight weeks following baseline (T2), and 16 weeks following baseline (T3). Participants will be recruited from primary care clinics and community organizations that provide support to older adults. The principal investigator (PI) / facilitator of the EFMT groups will be blinded to the results of outcome assessments until the end of the intervention phase of the study. The PI is a registered psychotherapist certified in delivering EFMT and will facilitate all groups.

Eligibility criteria

The PI will screen potential participants for the following inclusion criteria: participants will be community dwelling older adults 55 years of age and older with no existing therapeutic alliance with the PI; will self-report or have a diagnosis of anxiety; can speak English; and can commit to the eight-week program and three assessment phone calls with the RA. The presence of symptoms of anxiety will be assessed using the Geriatric Anxiety Inventory (GAI) with a cut off score of 10 which indicates the presence of anxiety (35). Exclusion criteria will be having begun or stopped psychotropic medications within the previous six weeks (36). Further exclusion criteria will be a Telephone Montreal Cognitive Assessment (T-MoCA) with a cut off score of 19 which indicates the possibility of mild cognitive impairment and would be beyond the scope of this study (37, 38). The T-MoCA is conducted by telephone and, due to COVID-19 restrictions, will be administered by the PI by telephone, who has been certified in the administration and scoring of the MoCA. Potential participants will be considered eligible to participate in the study if: their GAI score is < 10; and their T-MoCA score is < 19 (37, 38). The T-MoCA is conducted by telephone, and is a validated version of the MoCA that assesses phonemic fluency, word recall and orientation to day, date, and location, and does not use items that require paper and pencil or animal identification (38, 39). The T-MoCA is demonstrated to be accurate in detecting mild cognitive impairment (95% confidence interval) with excellent test-retest reliability and internal consistency (38, 39).

Interventions

Comparators

The comparator will be no treatment (treatment as usual) for the controlled wait list group. All participants will receive the intervention. All participants will receive T1, T2 and T3 assessments within 7–10 days of each timepoint.

Intervention description

EFMT is a group intervention traditionally consisting of eight weekly in person group meetings of 2.5 hours, with group sizes of between 10 and 12 participants. Due to COVID-19 restrictions, EFMT will be delivered by Zoom to groups of six participants and weekly meetings will be shortened to 1.5 hours to reduce Zoom fatigue. Each group meeting consists of a check-in period of five minutes, 20 minutes of silent meditation, 5–10 minutes of journaling about what arose for participants during the meditation, and a five-minute break. After journalling, each participant takes a turn and describes their meditation experience, with the PI offering empathic exploration.
EFMT poses little risk for participants. Meditation can sometimes cause uncomfortable feelings to arise when participants connect with emotions. Participants may decide to withdraw from the intervention if overwhelming emotions emerge. Participants may decline to answer questions during the reporting part of the meditation group. Participants may withdraw from the study at any time; however, study participants will be retained in the trial wherever possible to enable follow-up data collection and prevent missing data.

**Outcome Collection and Measures**

**Aim 1:** To determine if participants can be recruited, enrolled and retained, data will be gathered and measured on the number of potential participants referred and screened for eligibility, participants meeting eligibility requirements, participants enrolled, and participants completing the intervention. Dates defining the recruitment period will be reported. Variables such as changes to medications, beginning or stopping mental health counselling, and significant life events will be tracked by the RA at T3 data collection timepoint. Extraneous variables will be important to gather to identify other potential reasons for changes to secondary outcomes aside from EFMT.

**Aim 2:** To determine if participants can adhere to attendance of a minimum of six meetings, data on attendance will be gathered. Data for measures of adherence to meditation, journaling and reporting will also be gathered. Participants will not be required to practice between meetings, however data will be gathered on the frequency and duration of home practice meditation and journaling to explore whether there is a relationship to outcomes. Participants will complete weekly reporting forms to be emailed to the PI. The PI will keep an observational diary noting what works well and perceived areas of challenge.

**Aim 3:** To determine the secondary objective of whether participants who receive the intervention have decreased levels of anxiety compared to those participants who do not receive the intervention, the GAI will be used (35). Outcome measures will be collected using the GAI at T1, T2 and T3.

To determine the secondary objectives, the extent to which participants who receive the intervention experience changes to sleep quality and subjective memory functioning compared to participants who do not receive the intervention, the Pittsburgh Sleep Quality Index (PQSI) and the Multifactorial Memory Questionnaire (MMQ) will be used (40, 41).

**T1 data collection:** RA1 will collect demographic data and T1 outcome measures will be administered individually by telephone. Participants will be informed that they will be notified about the start date of their group. T2 and T3 post intervention data collection: At the end of the first intervention, all participants will be contacted by telephone to conduct individual T2 assessments. For T3 data collection all participants will be contacted by telephone by RA1 to conduct individual assessments.

**Sample size justification**

A sample size of 48 participants will allow for intervention group sizes of six participants and wait listed control group sizes of six participants. Small sample sizes of 10–20 participants or more are appropriate for pilot testing of adherence to interventions and this study will exceed those numbers (42, 43). Sample sizes should also be based on practical strategies such as the maximum number of participants that are reasonably feasible and possible within funding constraints (44). As COVID-19 protocols prohibit groups meeting in person, this study has moved to Zoom, an online privacy protected platform. Other COVID-19 adjustments pivots required will be shorter meetings of 1.5 hours to avoid Zoom fatigue, and smaller group sizes (45). This will be sufficient to meet the study objectives and determine whether a larger study is warranted.

**Recruitment**

Adults 55 years of age and older will be recruited through two primary care clinics in Eastern Ontario, Ontario-based community organizations that support older adults, and community referrals through traditional snowball effect (46). The PI will screen potential participants for eligibility. Referrals to the PI will be made by health care providers, staff at community-based organizations supporting older adults, and through community spread. Referees and self-referring community based potential participants will be informed of the study through email, advertisements on a local radio station's website, and social media. All costs associated with recruitment will be self-funded by the PI, a PhD candidate. Duration of recruitment will be monitored by the PI, and her PhD advisors. No financial incentives will be offered to participants. Potential benefits to participants will be instruction in a mindfulness-based meditation therapy group. The possible benefit to society at will be to determine the feasibility of a scalable treatment for older adults with anxiety.

**Randomization**

Random allocation will be conducted by the second author, immediately after each set of 12 participants has been enrolled into the study by the PI. Groups will begin on a rolling basis each time a block of 12 participants has been enrolled. To ensure a 1:1 random allocation between the intervention and control groups, the participants will be randomly using the random allocation function in Excel.

**Blinding**
RA will be blinded to participant allocation to ensure unbiased assessment administration and data collection throughout the study. Participants will be masked from the group to which they have been allocated. The PI will remain concealed to the outcome measurements data until all participants have completed the intervention and statistical analysis has begun. Unblinding and unmasking may unintentionally occur. It is possible that the RA may be unblinded to the allocation of participants who may unintentionally reveal their assignment to group during the collection of T2 outcome measures. This is a pragmatic reality of conducting a small scale self-funded PhD-based study.

**Data collection and management**

Collection of information at T1: T1 data collection will be conducted by the RA, a master’s level researcher trained by the PI in the administration of scoring of the three assessments to be administered. The RA will administer the GAI. The GAI has been validated for use in community dwelling adults over the age of 60, with excellent test-retest reliability of \( r = .91 \) to \( .95 \) (35, 47–49). This anxiety scale was selected because it is commonly used in a range of clinical settings (50). The RA will administer the PSQI and the MMQ (40, 51). The PQSI is a sleep quality and sleep disturbance assessment validated for use with community dwelling older adults (40). This measure was selected because sleep complaints are frequently associated with anxiety (52). The PQSI is a simple 19 item subjective measure of sleep quality and patterns of sleep using a 0 to 3 Likert scale (53). The PQSI has been demonstrated to have excellent test-retest reliability \( (r = .85 \sim .87) \) and internal consistency of Cronbach’s \( \alpha \) of .80 – .83 (40, 54, 55). The MMQ is a 21 item brief self-report assessment of subjective memory ability validated for use with community dwelling older adults (51, 56). This assessment measures satisfaction, ability and strategy use in memory. It was chosen because older adults with anxiety frequently report problems with memory (4, 5, 15–17). The MMQ has high test-retest reliability over time \( (.86 \sim .95) \) (56, 57). Cronbach’s \( \alpha \) internal consistency is good at .87 to .93 (51, 56, 58).

Collection of information at T2: All participants will be contacted by telephone by the RA to re-administer the GAI, PSQI and MMSQ within one week of completion of the intervention.

Collection of information at T3: All participants will be contacted by telephone by the RA to re-administer the GAI, PSQI and MMSQ, and to collect data on extraneous life events, within one week of completion of the intervention for the wait list control group. The RA will attempt to collect data from all participants whether or not all sessions are attended.

**Feasibility and acceptability outcomes:**

Feasibility and acceptability will be determined by participants’ adherence to all components of the intervention, attendance of 6 / 8 sessions and meditation, journaling and reporting. In the tradition of MBI research, the intervention will be considered complete if participants are able to attend a minimum of 6 / 8 meetings (59). Data will be gathered on adherence to meditation, journaling, and reporting aspects of the intervention through PI observation. It will be assumed that participants will be honest about meditation within the group, although direct evidence can only be inferred through observation (60). Participants are not required to practice at home, however data will be gathered on the frequency and duration of home practice meditation and journaling to explore whether there is a relationship to outcomes.

**Treatment fidelity:**

The PI received training and certification in a joint program with the University of Toronto, Faculty of Medicine, and Mt. Sinai Hospital, Toronto, Canada.

**Participant Retention**

The PI will encourage participant retention by sending reminder emails of group start dates to wait listed participants at four weeks, two weeks and one week prior to the beginning of the group.

**Statistical methods**

Data entry will be conducted by the RA. Data analysis will be conducted by the PI at the end of the study using SPSS v25. All data will be examined by running frequencies on each variable to determine if values are missing or out of range. Possible errors will be compared to raw data and corrected as necessary to ensure accuracy (60). As is recommended for pilot feasibility studies, descriptive statistics, such as mean, median, mode and standard deviation, will be used to describe and summarize the data (61, 62). Graphical displays will be presented to demonstrate and better understand the central tendency and dispersion of the data (60). Recruitment will be considered feasible if 70% of potential participants meet eligibility requirements consent to enroll (63); and if 48 participants can be enrolled within a three month period (16 participants recruited per month).

To determine whether there have been changes in the secondary outcomes descriptive statistics will be used to analyze and present demographic and baseline data. Categorical and ordinal data will be compared using chi-square. Ratio data will be compared using a \( t \)-test. The mean change in the intervention group and wait list control group outcomes will be compared post intervention (T3) using an independent samples \( t \)-test, and Cohen’s \( d \) will be calculated for effect size (60). Data from each of the groups will be combined to form a larger sample size...
to evaluate the effect of the intervention. Analysis of pooled data will be conducted using a paired sample t test and Cohen's d to determine the intervention effect over baseline measures. Change over time for the intervention group from T1 to T2 to T3 will be calculated by using repeated measures ANOVA to determine if change has occurred and/or is maintained in the intervention group.

Data management

All data forms will be uploaded to the Microsoft Teams environment, password protected and backed up in the Queen's University cloud storage. The RA will enter all data in SPSS. Data will be kept for seven to ten years after. Data will be held in a secure environment on Canadian servers in the Queen's University research data repository for faculty, students and staff (64).

Confidentiality

All information collected about potential participants will be destroyed should eligibility not be met for the study. All data collected from participants will be identified by a study identifier only to maintain participant confidentiality. No identifying information will be included when results of the study are shared. Participants will be asked to maintain confidentiality of other participants such as identifying information and meditation reflections. No record of the Zoom meetings will exist.

Auditing trial conduct

This trial will be audited by the second author for completeness and accuracy of data collection and retention of participants across arms of this study.

Ethics and dissemination

This trial has been approved by the Queen's University Health Sciences & Affiliated Teaching Hospitals Research Ethics Board (approval number REH-768-20). This clinical trial has been registered at ClinicalTrials.gov for accessibility by other researchers. This research study received the written support of the Prince Edward Family Health Team and the Queen's Family Health Team. The PI will inform the PhD committee of any changes to the protocol such as recruitment procedures, intervention or data collection and analyses. As appropriate, amendments will be requested of Queen's University HSREB and approvals received prior to any changes to this protocol. Protocol amendments will be communicated via ClinicalTrials.gov (ID NCT04415528) updates. Results will be disseminated through peer reviewed journals, international conferences, and primary care grand rounds.

Consent

Prior to screening for eligibility, each potential participant will receive an emailed copy of the Letter of Information / Informed Consent and will provide informed consent to the PI. Data gathered from screened potential participants not eligible to participate will be destroyed. The reason for ineligibility will be noted. All data will be anonymized. In the event of withdrawal from the study, the participant will have the choice of requesting that collected data be destroyed or to give consent to include data for analysis.

The purpose of this protocol is to ensure transparency and reproducibility of the results of this study. Therefore this protocol will be available publicly through journals and trial registries (65, 66). The deidentified data will be archived to Queen's University ScholarsPortal Dataverse, a repository for research data that is stored on Canadian servers in a secure environment, within three years of collection and will be available for sharing (67).

Discussion

Significant rates of anxiety amongst older adults can be expected to increase as the world population ages, and within the COVID-19 and post COVID-19 environment (24, 68, 69). Anxiety is a leading cause of disability in older adults (70). EFMT is a low-cost non-pharmacological treatment that could be offered in primary care and community settings. This trial will become the first RCT to determine the feasibility of EFMT for older adults with late life anxiety. Due to COVID-19, this group has been modified for delivery in an online format to ensure the participants’ safety. This trial will provide unique information to international researchers and clinicians regarding a novel treatment for late life anxiety. EFMT has the potential to provide older adults with the knowledge, skills, and practice to reduce anxiety.

Declarations

Trial status

Recruitment began August 3, 2020 and will continue until 48 participants have been recruited.

Ethics approval
This trial has been approved by the Queen's University Health Sciences & Affiliated Teaching Hospitals Research Ethics Board (approval number REH-768-20).

Consent for publication
All authors revised the manuscript for important content, agreed on the final version and consented to publication.

Availability of data and materials
Data will be kept for seven to ten years after it is analyzed and published. Data will be held in a secure environment on Canadian servers in the Queen's University Dataverse, a research data repository for faculty, students and staff (64).

Competing Interests
SR receives salary support from the Fonds de Recherche Québec Santé, held an investigator-initiated grant from Satellite Healthcare (end 2019), and holds shares in Aifred Health (biotechnology company).

Funding
This trial is self-funded by SH for PhD study.

Authors’ contributions
All authors made substantial contributions to the conception and design and final approval of the manuscript. All authors contributed to the design of the study and intellectual input. SH drafted the article and coordinated the revision phases.

Acknowledgements
Not applicable.

References
1. Schuurmans J, Van Balkom A. Late-life anxiety disorders: A review. Current Psychiatry Reports. 2011;Vol. 13:267–73.
2. Roser M. RHO-OE. Our World in Data. Burden of Disease. 2020.
3. Bland P. Tackling anxiety and depression in older people in primary care. Pract. 2012;256(1747):17–20.
4. Coryell W, Endicott J, Winokur G. Syndromes as Epiphenomena of Primary Major Depression: Outcome and Familial Psychopathology. Am J Psychiatry. 1992;149(1):100–7.
5. DeLuca AK, Lenze EJ, Mulsant BH, Butters MA, Karp JF, Dew MA, et al. Comorbid anxiety disorder in late life depression: Association with memory decline over four years. Int J Geriatr Psychiatry. 2005 Sep;20(9):848–54.
6. World Health Organization. 10 Facts on ageing and health [Internet]. 2018. Available from: http://www.who.int/features/factfiles/ageing/en/.
7. Mojtabai R, Olfson M. Major depression in community-dwelling middle-aged and older adults: Prevalence and 2- and 4-year follow-up symptoms. Psychol Med. 2004 May;34(4):623–34.
8. Petersen RC. Mild Cognitive Impairment. N Engl J Med. 2011;364(23):2227–34.
9. Busse A, Hensel A, Gühne U, Angermeyer MC, Riedel-Heller SG. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology. 2006;67(12):2176–85.
10. Carlo A, Di, Lamassa M, Baldereschi M, Inzitari M, Scafato E, Farchi G, et al. CIND and MCI in the Italian elderly Frequency, vascular risk factors, progression to dementia. Neurology [Internet]. 2007;68(22):1909–16. Available from: www.neurology.org.
11. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med [Internet]. 2008 Mar 18;148(6):427–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18347351.
12. Manly JJ, Tang M, Schupf N, Stem Y, Vonsattel JP, Mayeux RP. Frequency and Course of Mild Cognitive Impairment in a Multiethnic Community. Ann Neurol. 2008;63(4):494–506.
13. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, et al. Prevalence and Classification of Mild Cognitive Impairment in the Cardiovascular Health Study Cognition Study: Part 1. Arch Neurol. 2003;60(10):1385–9.
14. Smith A. MCI in risk society: Biomarkers and the biopolitics of dementia. Gerontologist. 2015;55(Suppl_2):639.
15. Gerolimatos LA, Ciliberti CM, Gregg JJ, Nazem S, Bamonti PM, Cavanagh CE, et al. Development and preliminary evaluation of the anxiety in cognitive impairment and dementia (ACID) scales. Int Psychogeriatrics. 2015;27(11):1825–38.

16. Seignourel PJ, Kunik ME, Snow L, Wilson N, Stanley M. Anxiety in dementia: A critical review. Clin Psychol Rev. 2008;28(7):1071–82.

17. Yochim BP, Mueller AE, Segal DL. Late life anxiety is associated with decreased memory and executive functioning in community dwelling older adults. J Anxiety Disord [Internet]. 2013;27(6):567–75. Available from: http://dx.doi.org/10.1016/j.janxdis.2012.10.010.

18. Rozzini L, Chilovi BV, Peli M, Conti M, Rozzini R, Trabucchi M, et al. Anxiety symptoms in mild cognitive impairment. Int J Geriatr Psychiatry. 2009;24(3):300–5.

19. Decanç K. Measuring Successful Aging with Respect for Preferences of Older Persons. Journals Gerontol - Ser B Psychol Sci Soc Sci. 2019 Jan 10;74(2):364–72.

20. Banerjee S, Helliger J, Dewy M, Romeo R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): A Randomised, Multicentre, Double-blind, Plac. Lancet. 2011;378(9789):403–11.

21. Nezafati V. Antidepressants and cardiovascular adverse events: A narrative review. ARYA Atheroscler. 2015;11(5):295–304.

22. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: Population-based cohort study. BMJ. 2011 Aug;13(7819):354–69. 343(.

23. Torres-Platas SG, Escobar S, Belliveau C, Wu J, Sasi N, Fotsos J, et al. Mindfulness-Based Cognitive Therapy Intervention for the Treatment of Late-Life Depression and Anxiety Symptoms in Primary Care: A Randomized Controlled Trial. Psychother Psychosom. 2019;88(4):254–6.

24. Peteet JR. COVID-19 Anxiety. J Relig Health. 2020 Oct 1;59(5):2203–4.

25. Geiger PJ, Boggero IA, Brake CA, Caldera CA, Combs HL, Peters JR, et al. Mindfulness-Based Interventions for Older Adults: a Review of the Effects on Physical and Emotional Well-Being. Mindfulness (N Y). 2016 Apr 1;7(2):296–307.

26. Goyal M, Singh S, Sibinga EMS, Gould NF, Rowland-Seymour A, Sharma R, et al. Meditation programs for psychological stress and well-being: A systematic review and meta-analysis. JAMA Intern Med. 2014;174(3):357–68.

27. Gayner B, Esplen MJ, De Roche P, Wong J, Bishop S, Kavanagh L, et al. A randomized controlled trial of mindfulness-based stress reduction to manage affective symptoms and improve quality of life in gay men living with HIV. J Behav Med. 2012 Jun;35(3):272–85.

28. Gayner B. Orientation to emotion-focused mindfulness meditation [Internet]. Emotion-focused mindfulness therapy. 2019 [cited 2019 Nov 9]. Available from: https://mindfulfeeling.ca/about-emotion-focused-therapy/orientation-to-efmt-meditation/.

29. Foulk MA, Ingersoll-Dayton B, Kavanagh N, Robinson E, Kales HC. Mindfulness-Based Cognitive Therapy With Older Adults: An Exploratory Study. J Gerontol Soc Work. 2014;57(5):498–520.

30. Kabat-Zinn J. Full catastrophe living: Using the wisdom of your body and mind to face stress, pain, and illness. New York: Delacorte Press; 1990.

31. Shapero BG, Greenberg J, Pedrelli P, de Jong M, Desbordes G. Mindfulness-Based Interventions in Psychiatry. Focus (Madison). 2018 Jan;16(1):32–9.

32. Neff KD. Self-Compassion, Self-Esteem, and Well-Being. Soc Personal Psychol Compass. 2011;5(1):1–12.

33. Gayner B. Emotion-focused mindfulness therapy. Pers Exp Psychother [Internet]. 2019;18(1):98–120. Available from: https://doi.org/10.1080/14779757.2019.1572026.

34. Wisco R, Haber C. A feasibility study of an emotion focused-mindfulness group. Press.

35. Johnco C, Knight A, Tadic D, Wuthrich VM, Pachana NA, Oude Voshaar RC. Psychometric properties of the Geriatric Anxiety Inventory (GAI) and its short-form (GAI-SF) in a clinical and non-clinical sample of older adults. Int Psychogeriatrics. 2015 Jul;23(7):1089–97. 27(.

36. Innes KE, Selfe TK, Brown CJ, Rose KM, Thompson-Heisterman A. The effects of meditation on perceived stress and related indices of psychological status and sympathetic activation in persons with Alzheimer’s disease and their caregivers: A pilot study. Evidence-based Complement Altern Med. 2012;2012:6.

37. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. J Am Geriatr Soc. 2005;53(4):695–9.

38. Pendlebury ST, Welch SJV, Cuthbertson FC, Mariz J, Mehta Z, Rothwell PM. Telephone assessment of cognition after transient ischemic attack and stroke: Modified telephone interview of cognitive status and telephone montreal cognitive assessment versus face-to-face montreal cognitive assessment and neuropsychological battery. Stroke. 2013 Jan;44(1):227–9.

39. Wong A, Nyenhuis D, Black SE, Law LSN, Lo ESK, Kwan PWE, et al. Montreal Cognitive Assessment 5-Minute Protocol Is a Brief, Valid, Reliable, and Feasible Cognitive Screen for Telephone Administration. Stroke. 2015 Apr 20;46(4):1059–64.

40. Carpenter JS, Andrykowski MA. Pyschometric Evaluation of the Pittsburgh Sleep Quality Index. J Psychosom Res. 1998;45(1):5–13.
41. Troyer AK, Rich JB. Professional Manual Multifactorial Memory Questionnaire [Internet]. Toronto: Baycrest Centre for Geriatric Care; 2018. 37 p. Available from:.
42. Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Heal. 2008 Apr;31(2):180–91.
43. Moore CG, Carter RE, Nietert PJ, Stewart PW. Recommendations for planning pilot studies in clinical and translational research. Clin Transl Sci. 2011;4(5):332–7.
44. Bacchetti P. Current sample size conventions: Flaws, harms, and alternatives. BMC Med [Internet]. 2010;8(1):17. Available from: http://www.biomedcentral.com/1741-7015/8/17.
45. Wiederhold BK. Connecting through Technology during the Coronavirus Disease 2019 Pandemic: Avoiding “zoom Fatigue.” Cyberpsychology, Behav Soc Netw. 2020 Jul 1;23(7):437–8.
46. Sadler GR, Lee HC, Lim RSH, Fullerton J. Recruitment of hard-to-reach population subgroups via adaptations of the snowball sampling strategy. Nurs Heal Sci. 2010 Sep;12(3):369–74.
47. Pachana NA, Byrne GJ, Siddle H, Koloski N, Harley E, Arnold E. Development and validation of the Geriatric Anxiety Inventory. Int Psychogeriatrics. 2007 Feb;19(1):103–14.
48. Byrne GJ, Pachana NA, Arnold L, Chalk JB, Appadurai K. Performance characteristics of the geriatric anxiety inventory in memory clinic attendees. Alzheimer’s Dement. 2008 Jul;4:T441–2.
49. Helmes E, Ward BG. Mindfulness-based cognitive therapy for anxiety symptoms in older adults in residential care. Aging Ment Heal. 2017 Mar;4;21(3):272–8.
50. Sundquist J, Lilja Å, Palmér K, Memon AA, Wang X, Johansson LM, et al. Mindfulness group therapy in primary care patients with depression, anxiety and stress and adjustment disorders: Randomised controlled trial. Br J Psychiatry. 2015 Feb 1;206(2):128–35.
51. Troyer AK, Rich JB. Psychometric Properties of a New Metamemory Questionnaire for Older Adults. J Gerontol [Internet]. 2002;57(1):19–27. Available from: https://academic.oup.com/psychsocgerontology/article-abstract/57/1/P19/576214.
52. Yang C-M, Lo H-S, Spielman AJ. Sleep disturbances in anxiety disorders. In: Pandi-Perumal SR, Monti JM, editors. Clinical Pharmacology of Sleep. Switzerland: Birkhauser Basal; 2006. pp. 81–100.
53. Smyth C. Sleep Quality in Older Adults. AJN [Internet]. 2008;108(5):42–50. Available from: http://www.nursingcenter.com.
54. Cole JC, Motivala SJ, Buysse DJ, Oxman MN, Levin MJ, Irwin MR. Validation of a 3-Factor Scoring Model for the Pittsburgh Sleep Quality Index in Older Adults. Instrum Methodolog. 2006;29(1):112–6.
55. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: A New Instrument for Psychiatric Practice and Research. Psychiatry Res. 1989;28(2):193–5.
56. Troyer AK, Leach L, Vamendorris S, Rich JB. The measurement of participant-reported memory across diverse populations and settings: a systematic review and meta-analysis of the Multifactorial Memory Questionnaire. Memory. 2019 Aug 9;27(3):931–42.
57. Shaikh KT, Tatham EL, Parikh PK, McCreath GA, Rich JB, Troyer AK. Development and Psychometric Validation of a Questionnaire Assessing the Impact of Memory Changes in Older Adults. Gerontologist. 2019 Jul 16;59(4):e248–57.
58. Yang HL, Chu H, Kao CC, Chiu HL, Tseng IJ, Tseng P, et al. Development and effectiveness of virtual interactive working memory training for older people with mild cognitive impairment: A single-blind randomised controlled trial. Age Ageing. 2019;48(4):519–25.
59. Santorelli SF, Florence Meleo-Meyer MA, Koerbel L, Kabat-Zinn J. Mindfulness-Based Stress Reduction (MBSR) Authorized Curriculum Guide [Internet]. 2017. Available from: https://www.umassmed.edu/globalassets/center-for-mindfulness/documents/mbsr-curriculum-guide-2017.pdf.
60. Plichtar Kellar S, Kelvin EA. Munro's statistical methods for health care research. 6th ed. Philadelphia: Wolters Kluwer; 2013. 563 p.
61. Lee W. The statistical interpretation of pilot trials: Should significance thresholds be reconsidered? BMC Med Res Methodol. 2014 Mar;20(1):41–1. 14(.
62. Lancaster GA, Dodd S, Williamson PR. Correspondence Design and analysis of pilot studies: recommendations for good practice. Vol. 10, Journal of Evaluation in Clinical Practice. 2004.
63. Walters SJ, Bonacho I, Henrques-Cadby A, Bortolami O, Flight L, Hind D, et al. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. BMJ Open [Internet]. 2017;7:15276. Available from: http://www.isrctn.com/.
64. Scholars Portal Dataverse [Internet]. Queen's University. [cited 2010 Oct 30]. Available from: https://dataverse.scholarsportal.info/dataverse/queens.
65. Křeža-Jerić C. Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1). BMJ 2005 Apr. 2005;330(7497):956–8. 330(7497 :956–8.
66. Deangelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical Trial Registration: A Statement From the International Committee of Medical Journal Editors. JAMA [Internet]. 2004 [cited 2020 Nov 7];292(11):1363–4. Available from: https://doi.org/10.1001/jama.292.11.1363.

67. Queens University. Queens University Dataverse [Internet]. Queens University. 2020 [cited 2020 Nov 7]. Available from: https://dataverse.scholarsportal.info/dataverse/queens.

68. Ionson E, Limbachia J, Rej S, Puka K, Newman RI, Wetmore S, et al. Effects of Sahaj Samadhi meditation on heart rate variability and depressive symptoms in patients with late-life depression. Br J Psychiatry. 2019 Apr 1;214(4):218–24.

69. Cai X, Hu X, Ekumi IO, Wang J, An Y, Li Z, et al. Psychological Distress and Its Correlates Among COVID-19 Survivors During Early Convalescence Across Age Groups. Am J Geriatr Psychiatry. 2020 Oct 1;28(10):1030–9.

70. World Health Organization. Closing the gap in a generation: Health equity through action on the social determinants of health [Internet]. Geneva, Switzerland; 2008. Available from: https://apps.who.int/iris/bitstream/handle/10665/43943/9789241563703_eng.pdf?sequence=1.